Stem Cell and Exosome Therapy Now Available in Texas – Carroll County Mirror-Democrat
Texas medical facilities launch stem cell and exosome therapy programs for orthopedic and degenerative conditions.
-
-
Once-Restricted Peptides May Make A Return: What This Means For Skin Care – NDTV
Previously restricted peptides may soon enter consumer skin care products as regulators reassess classification standards.
-
The wellness world is eager for RFK Jr.’s promised move on peptides – NPR
RFK Jr. signals potential FDA policy changes on peptides, drawing enthusiasm from wellness advocates and concern from medical experts.
-
A new way to sell weight loss drugs?
Pharmacies and telehealth firms launch subscription models for GLP-1 drugs, disrupting traditional weight loss treatment delivery.
-
How GLP-1 weight loss drugs are shaping the future of European food demand – Food Ingredients First
GLP-1 weight loss drugs are forcing European food companies to rethink products as consumer demand patterns shift dramatically.
-
What Are the Risks of HRT in Breast Cancer Survivors? – Cancer Therapy Advisor
New research examines HRT risks for breast cancer survivors, finding increased recurrence rates but highlighting need for individualized decisions.
-
Q&A: Should you trust trending peptide injections? – Medical Xpress
Social media’s peptide craze lacks FDA oversight and clinical evidence, raising safety concerns among medical experts.
-
Evidence Suggest Fewer GLP-1 Doses Maintain Weight Loss – Medscape
New evidence suggests patients may maintain GLP-1 weight loss with less frequent dosing after reaching their goals.
-
ProHealth Longevity BPC‑157 Claims Evaluated: Most Effective BPC157 Peptide Brand on the Market (2026) – The Manila Times
Medical experts question ProHealth Longevity’s BPC-157 claims as the unapproved peptide lacks human clinical trial data.
-
Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly – CNBC
Novo Nordisk introduces multi-month Wegovy subscriptions to improve access and adherence for obesity treatment patients.
